Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy.
about
Preadministration of High-Dose Salicylates, Suppressors of NF- B Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation TherapyAkt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extractInsulin-like Growth Factor 1 Signaling Axis Meets p53 Genome Protection PathwaysDiets high in selenium and isoflavones decrease androgen-regulated gene expression in healthy rat dorsolateral prostatemiR-Synth: a computational resource for the design of multi-site multi-target synthetic miRNAsCurcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cellsA computational framework for the topological analysis and targeted disruption of signal transduction networks.Evidence for a pro-proliferative feedback loop in prostate cancer: the role of Epac1 and COX-2-dependent pathways.Combination of selenium and green tea improves the efficacy of chemoprevention in a rat colorectal cancer model by modulating genetic and epigenetic biomarkers.Down-regulation of vinculin upon MK886-induced apoptosis in LN18 glioblastoma cellsThe 26S proteasome complex: an attractive target for cancer therapySignaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for TherapySynergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cellsMorphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients.Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistanceMultifocal angiostatic therapy: an update.Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis?Gankyrin drives malignant transformation of chronic liver damage-mediated fibrosis via the Rac1/JNK pathway.cGMP-independent anti-tumour actions of the inhibitor of soluble guanylyl cyclase, ODQ, in prostate cancer cell lines.Role of type 2C protein phosphatases in growth regulation and in cellular stress signaling.Timing of supplementation of selenium and isoflavones determines prostate cancer risk factor reduction in rats.Isoflavones and the prevention of breast and prostate cancer: new perspectives opened by nutrigenomics.Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R.Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cellsDclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells.Targeting anoikis resistance in prostate cancer metastasis.Evaluation of 12-lipoxygenase (12-LOX) and plasminogen activator inhibitor 1 (PAI-1) as prognostic markers in prostate cancer.The role of vitamin D in cancer prevention and treatment.The role of vitamin D in cancer prevention and treatment.Targeting malignant mitochondria with therapeutic peptides.RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acidFisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.Nexrutine inhibits azoxymethane-induced colonic aberrant crypt formation in rat colon and induced apoptotic cell death in colon adenocarcinoma cells.Synergistic anti-tumor activity of isochaihulactone and paclitaxel on human lung cancer cells.Effects of selenite and genistein on G2/M cell cycle arrest and apoptosis in human prostate cancer cells.Nutrigenomics and cancer.Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine.The role of SRC family kinases in prostate cancer.Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R.
P2860
Q22299231-4431ABD0-CA87-42AE-B290-1717ABAFE970Q24680138-DEB44DD7-AC83-4987-80D4-2951CC594A5FQ26742114-AF9ACE14-6C60-4CEC-9D4B-C395ACFDE9FBQ28565580-1A0A8372-546D-451E-BFC4-CB879EA3876DQ33635585-C5954DA0-6B33-4106-8260-4E25436706E1Q34126876-F5BA7AAD-9174-46FC-BDA8-2DD6F1603270Q34680360-0607AF39-C294-49BA-8E99-9A8EDAB52CD5Q34707066-F1F66EB6-EA4C-4527-B505-CD2544F4FAF0Q34745779-B9744E37-F543-499C-BBB2-712B7315ED91Q35061682-534016CE-78C0-4663-9D36-94864CEB0070Q35624079-71AC7BFC-AADA-4969-904E-253A224E2EB1Q35855640-40100243-8326-46D3-9644-83F0AC0FE205Q36078490-5EEBDEAF-BDF3-4089-90BC-185D7E5E2276Q36184798-F8E8D034-F886-4B40-8037-23629B57DA74Q36282200-CD8A45D6-8DD4-4B3A-92A9-A41C88C1F836Q36311166-14DF2FD3-661F-4E1F-9F37-68CD58950DE0Q36343101-48739784-680F-4CEB-9265-A51E7CD33C58Q36346927-7042DA01-89C3-47FE-A6FD-0DB028B390FFQ37002324-DF29AA61-5D24-4FEB-84F0-54AC7C2D594FQ37027389-E089C41C-813A-44E4-8229-D9FDE60DB887Q37040298-A4477864-9161-43CC-B2E0-A9CEF10021C1Q37173328-7781D64A-19BD-4573-A978-84E1F9DB063FQ37287442-84E3ACD5-7A54-4563-8ADF-B98750299F7BQ37332147-4453D4D8-2E3D-41ED-99E7-21221A2E44A5Q37401875-3B997DF7-3E06-4F04-BD66-9BEF3617E9A7Q37618755-4315C317-E110-4CA0-842F-3FC6C8367E08Q37691830-A6A74B41-D13B-41FD-9ED6-BE9201383C31Q37695659-4C0D09BD-FDC2-4B38-BAA1-1003B7403C8EQ37761548-616A52AC-B21C-4EE7-BB8F-185FECED007EQ38004753-B23867B3-1BD4-4B27-96D5-DAE1D5D5625CQ38040407-C6DAD301-55A4-4D18-8197-57955A290D75Q38263467-E539867E-1664-43CD-A74C-AC4AB9B4F38FQ38739235-3C29107C-74BD-4AE2-8190-1F29EBEF0261Q38844888-0F5C0E25-3660-4107-B08B-1849F8497C36Q39578313-C6FB0AE0-EE45-4B69-85FF-69E172F06D83Q39859901-EBAD4456-A43F-407B-9B5E-BB6F673C91CAQ39991273-59F4FE98-7529-404E-99A4-40F9973A7641Q40046885-F1204B4A-D8E2-4EDC-8C33-22EFF521ED59Q40055337-0C77DF3C-5A12-405D-B01E-F16ACFA365DAQ40071695-D96370CA-0291-4FA1-BFC7-5FB544369DE6
P2860
Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Targeting multiple signaling p ...... cal signal modulation therapy.
@ast
Targeting multiple signaling p ...... cal signal modulation therapy.
@en
type
label
Targeting multiple signaling p ...... cal signal modulation therapy.
@ast
Targeting multiple signaling p ...... cal signal modulation therapy.
@en
prefLabel
Targeting multiple signaling p ...... cal signal modulation therapy.
@ast
Targeting multiple signaling p ...... cal signal modulation therapy.
@en
P356
P1476
Targeting multiple signaling p ...... cal signal modulation therapy.
@en
P2093
Mark F McCarty
P304
P356
10.1177/1534735404270757
P577
2004-12-01T00:00:00Z